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Abstract 
Background: High-sensitivity assays for cardiac troponin T (hs-cTnT) are sometimes 
used to rapidly rule-out acute myocardial infarction.  
Purpose: To estimate the ability of a single hs-cTnT concentration below the limit of 
detection (<5ng/L) and non-ischemic ECG to rule-out myocardial infarction in adults 
presenting to the emergency department with chest pain. 
Data sources Embase and Medline without language restrictions (1 January 2008 to 14 
December 2016).   
Study selection: Cohort studies involving adults  presenting to the emergency department 
with possible acute coronary syndrome in whom ECG and hs-cTnT were measured and 
myocardial infarction outcomes adjudicated during initial hospitalization. 
Data	extraction:	Investigators of cohort studies provided data on numbers of low-risk 
(no new ischemia on ECG and hs-cTnT measurements below 5ng/L) patients, and 
numbers of patients who had a myocardial infarction during hospital admission (main 
outcome), or a major adverse cardiac event (MACE) or death within 30 days (secondary 
outcomes), by risk classification (low-risk, not low-risk). Two independent 
epidemiologists rated risk of bias of the cohort studies.  
Data synthesis: Of 9269 patients in 11 cohort studies 2825 (30.5%) were classified low-
risk. Fourteen (0.5%) low-risk patients had a myocardial infarction. Sensitivity of the risk 
classification for myocardial infarction ranged from 87.5% to 100 in individual studies. 
The pooled estimated sensitivity was 98.7% (95%CI: 96.6 to 99.5). Sensitivity for 30-day 
MACE ranged from 87.9% to 100% while the pooled sensitivity was 97.9% (93.7 to 
99.3). No low-risk patients died. 
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Limitations: Few studies; variation in timing and methods of reference standard troponin 
tests used to diagnose myocardial infarction; heterogeneity in risk and prevalence of 
infarction across studies. 
Conclusion: A single hs-cTnT below the limit of detection in combination with a non-
ischemic ECG may successfully rule-out myocardial infarction in patients presenting to 
emergency departments with possible emergency acute coronary syndrome.  
 
Primary Funding Source: Emergency Care Foundation 
 
  
 
 
 
Key words: Chest Pain, Acute Coronary Syndrome, Myocardial Infarction, Troponin, 
Emergency department, Emergency room  
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Introduction 
 
Only 10-20% of patients who present to emergency departments (EDs) with suspected 
cardiac-related chest pain are finally diagnosed with an acute myocardial infarction 
(AMI).(1-3) Researchers have developed rule-out strategies to identify non-AMI chest 
pain patients for safe, early discharge to outpatient management.(1-3) A high sensitivity 
assay for cardiac troponin T (hs-cTnT) enables more reliable detection of very low 
concentrations of troponin T. A single hs-cTnT measurement below the limit of detection 
(LoD) or limit of blank (LoB) may rule-out AMI.(4,5) These cut-offs have appeared as 
part of diagnostic pathways in European guidelines(6,7), yet the underpinning evidence 
presented was from a small number of studies some of which were affected by laboratory 
calibration errors resulting in lower than true hs-cTnT concentrations, including the 
largest study to advocate this approach to date.(8,9) In that retrospective analysis of 
14,636 chest pain patients, 61% of whom had an initial hs-cTnT measurement of <5ng/l 
(<LoD) and no ischemic ECG ST-segment changes.  Of these 0.2% incurred an AMI 
within 30 days of their presentation at the emergency department.  However, the 
retrospective design of this large study included a number of methodological 
compromises.(9) Two meta-analyses considered a single hs-cTn measurement below the 
LoD to rule-out AMI, however, one combined the results from two (3 ng/L and 5 ng/L) 
thresholds(10)and the other combined studies of hs-cTnT with studies of hs-cTnI less the 
LoD.(11) Both these approaches are flawed and mean the resultant, pooled statistics 
cannot be used to evaluate an hs-cTnT<LoD rule-out strategy. For these reasons advocacy 
for rule-out of MI when hs-cTnT <LoD is premature. However, if findings can be 
validated across multiple studies free of these limitations, then this approach could enable 
safe discharge of many more patients than achieved by current practice.  
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Our objective was to test the utility of a single hs-cTnT measurement below the LoD 
combined with an ECG without evidence of acute ischemia to safely identify patients at 
low-risk of AMI on presentation to the ED. 	
 
Methods 
We developed and followed a protocol (Supplementary material) and report according to 
the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA).(12)  
 
Data Sources and Searches 
We searched MEDLINE and EMBASE without language restrictions from 1 January 
2008 (when the hs-cTnT assay was first released) to 14 December 2016 using the terms: 
chest pain, chest discomfort, acute coronary syndrome, acute myocardial infarction, 
troponin, high sensitive/sensitivity, and emergency room/department (See Supplement).  
 
Study Selection 
Two reviewers (JWP and JY) independently screened titles and abstracts including 
conference abstracts and identified potential cohorts from the full-text articles. Where 
only conference abstracts were available, a further manual search was conducted based on 
author names for full-text articles.  A third reviewer (MT) was used to confirm cohorts for 
exclusion or inclusion. Principal investigators and lead authors for each eligible cohort 
were contacted. We excluded cohorts if the investigators were unable to provide data.   
 
Eligibility studies were prospective studies, published in peer review journals, recruited 
patients investigated in the ED for possible Acute Coronary Syndrome with ECG and hs-
cTnT and reported on our primary endpoint. We excluded studies that did not: collect data 
prospectively, adjudicate for AMI using the Universal Definition (see Supplement), or 
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address the calibration error of hs-cTnT batch numbers 157120, 160197, and 163704 
(produced between October 2009 and April 2012 and with latest expiry date October 
2012) by confirming no samples from affected batches were included in the original 
study, or by excluding samples from affected batches, or by new value assignment of the 
calibrator set applied to the original analyzer results (ie therefore providing exact, correct, 
results).   
 
Data Synthesis and Analysis 
The primary endpoint was index admission AMI according to the global taskforce 
definition requiring biochemical evidence of myocardial necrosis and clinical evidence of 
myocardial ischemia (ischemic symptoms, ECG changes, or imaging. evidence).(13) 
Patients with ST-Elevatetion Myocardial Infarction on initial ECG were excluded from 
analysis. There was no restriction on the troponin assay used for adjudication of AMI.  
There were two secondary endpoints: death in 30 days or a major adverse cardiac event 
(MACE) within 30 days after first presentation (including any during the initial hospital 
attendance). MACE included: death, cardiac arrest, emergency revascularization 
procedure, cardiogenic shock, ventricular arrhythmia or high-degree atrioventricular 
block needing intervention, and AMI.(14)  
 
The index test was an ECG and hs-cTnT at ED presentation.  Patients with a negative test 
defined as no new ischemic changes on ECG (ST segment changes or T wave inversion 
indicative of cardiac ischemia) and hs-cTnT concentration <LoD (5ng/L) of Roche 
Diagnostics hs-cTnT assay (also sometimes called the fifth generation troponin T assay. 
Table S1) were classified as low-risk for AMI and subsequent adverse events. The 
secondary index test utilized the LoB (3 ng/L) instead of the LoD. 
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We calculated the proportion of patients in each study classified as being at low risk for 
AMI using the index test. We validated the clinical performance of the index test by 
calculating the sensitivity (1-false negative rate) of non-low risk classification for AMI 
during the initial hospital attendance. The c2 test for equality of sensitivities (null 
hypothesis) was applied. We also report the Negative Predictive Value (NPV) as this has 
been used to assess biomarker performance in a number of troponin biomarker studies, 
but as this is prevalence-dependent we chose to use sensitivity for primary analysis. For 
completeness, we also reported test specificity and Positive Predictive Value (PPV), 
although we note that it is not currently intended that patients should be risk stratified as 
high-risk (rule-in) using the proposed strategy. For the secondary analysis, we assessed 
the clinical performance of the index test for prediction of MACE within 30 days of 
presentation by calculating the test sensitivity, NPV, specificity and PPV.  Additional 
analyses were conducted using the LoB as the diagnostic threshold for hs-cTnT. The 
summary estimates of sensitivity (principal summary measure), specificity, NPV, PPV 
(and their 95% confidence interval reflecting the degree of heterogeneity between studies) 
were obtained using a random effects bivariate model.(15) A summary receiver operator 
characteristic curve was used to reflect the discriminative ability of the index test. We 
quantified heterogeneity with the I2 statistic which reflects the proportion of variation in 
point estimates among studies beyond that expected by chance. I2 <25%, 25% to <75%, 
and ≥75% were considered to represent low, moderate, and high heterogeneity 
respectively.(16) 
We conducted all analyses using R version 3.2.2(17) (package ÔmadaÕ for meta-analysis 
of diagnostic accuracy). 
 
Data extraction and quality assessment 
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Study investigators supplied summary 2x2 tables for each test with AMI, MACE and 
mortality outcomes along with a summary of cohort demographics.  
 
Two independent epidemiologists (SJL & LKS) who had not participated in any of the 
included studies adjudicated study risk of bias and applicability for AMI. Assessments 
were made independently, followed by a meeting in which discrepancies were identified 
and resolved by discussion. Where required, questions were posed to study authors for 
further clarification before the final assessment. The evaluation was carried out using the 
QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies Ðversion 2) tool.(18) 
Where available, information about the patient characteristics and AMI prevalence for 
excluded patients was also assessed to inform judgment of risk of bias. 
 
Role of the Funding Source 
The Emergency Care Foundation (ECF) administers a fellowship grant enabling JWP to 
undertake this and other work.  The ECF had no role in design, conduct, or publication of 
this research. No specific grants or commercial funding were obtained for this study. 
 
Results 
The systematic search identified 596 citations from which 27 potential eligible cohorts 
were identified (Figure 1).  Lead authors and primary investigators were contacted. A 
further 16 cohorts were excluded; Table S2.   
 
Study populations 
Eleven cohorts with a total of 9269 participants (range: 194 to 2831) were included (Table 
1).(4,19-27) Overall 63.9% of participants were male (cohort range 54.6% to 70.6%) with 
a mean age of 61.1 years (cohort range of mean age 54.5 to 70.6). AMI prevalence ranged 
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from 7.0% to 23.3%. The overall prevalence of AMI for the pooled populations was 
15.4%.  Study inclusion criteria were reasonably consistent, however there were some 
differences in exclusion: renal failure requiring dialysis was specified in three 
studies(4,19,25), one study excluded atypical presentations like fatigue or 
dizziness(26)(Table S3).  
 
Study methods and risk of bias 
All studies prospectively recruited patients presenting to the EDs with symptoms 
suggestive of acute coronary syndrome.  Three studies enrolled a consecutive sample of 
patients with all eligible patients included in the present analysis, and appropriate 
exclusions (Table S4).(23-25) Four other cohorts enrolled consecutive patients during set 
times of the day.(19,20,27) Two studies did not perform a second troponin on some low-
risk patients(25,26)  Overall, nine cohorts were classified as high or unclear risk of bias 
for patient selection and/or study flow.(4,20-23,25-27)  Of these, three studies reported 
additional information on patient characteristics and outcomes in eligible patients not-
enrolled or not included in the analysis; with each study reporting similar or lower 
AMI/ACS rates in excluded patients.(21,26-28) One study reported on the proportion of 
index troponin tests that were indeterminate due to haemolysed samples 
(11/1167=0.9%).(27) All studies performed the index test (hs-cTnT and ECG) and 
reference standard performed according to a pre-specified protocol for data collection and 
reported data to allow classification at the pre-specified LoD and LoB cut-points. 
 
All studies followed global taskforce recommendations to define AMI and 10 studies used 
independent adjudication to verify endpoints.  Second blood samples for clinical care 
purposes and later outcome adjudication were drawn at six or more hours after symptom 
onset except in the two studies where no second blood draw was made for some low risk 
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patients (25,26) and in one study where some low-risk patients were discharged after a 
second blood sample 2-hours after the first.(22)  Six cohorts used hs-cTnT clinically and 
therefore also for adjudication purposes(19,22-24,26,27) one of which had been re-
adjudicated after the initial study.(19,29). 
 
Other cohorts used a variety of clinical troponins and those adjudicating outcomes were 
blinded to hs-cTnT concentrations (Table S3). If the clinical troponin concentration was 
elevated, but a rise or fall was not recorded, then other causes of a raised troponin 
concentration were considered by the adjudicators. If no clear alternative cause of the 
troponin rise was evident, and if the clinical presentation was suggestive of an acute 
coronary syndrome, an adjudicated diagnosis of AMI was made. In all studies with the 
exception of Nelson(22), experienced clinical researchers who were blinded to the study 
protocol adjudicated for the outcomes. In the Nelson cohort adjudication was not blinded 
to the study protocol, but one of two cardiologists assessed the outcome and, where 
necessary, an independent cardiologist assessed unclear assessments (Table S3). Six 
studies received supporting grants or reagents from Roche.(4,19,20,23,25) 
 
Primary Outcome 
The index test classified 30.6% (range: 3.8% to 73.5%) of patients as being at low-risk of 
AMI (Table S5). Overall, there were 14 patients with a negative test who had an AMI (i.e. 
false negative cases). In 7 of these cases the time between symptom onset and blood 
sampling was <3 hours (4 <2 hours). The pooled estimate sensitivity of this test was 
98.7% (95%CI: 96.6 to 99.5), with sensitivities of individual cohorts between 87.5% and 
100% (Figure 2; test for equality of sensitivities p <0.001). The heterogeneity was high 
(I2=90.3%). The pooled NPV was 99.3% (97.3 to 99.8) and varied from 96.5% to 100% 
(Figure 3). The pooled negative likelihood ratio was 0.04 (0.02 to 0.08). The cohort with 
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the lowest sensitivity (RATPAC) had greatest proportion of patients classified as low-risk 
(73.5%; Table S5). The range of specificities was broad (Figure S2; See also summary 
receiver operator characteristic curve, Figure S1). 
 
Secondary Outcomes 
Eight cohorts (total n= 8059) provided data on MACE within 30 days. There were 20 
MACE events (including index admission AMI) following a negative index test including 
index admission AMI. The pooled estimate sensitivity for MACE was 98.0% (94.7 to 
99.3), with sensitivities of individual cohorts ranging from 87.9% to 100% (Figure S4). 
 
126 (1.3%) patients died within the 30-day follow-up period, none of whom had been 
classified as low-risk by the primary index test (Table S5). 
 
Sensitivity Analysis 
Nine cohorts provided data on index AMI outcomes with the LoB as the threshold for hs-
cTnT.  19.6% of patients were classified as low risk (hs-TnT<LoB and no ischemic 
changes on ECG) with a pooled sensitivity of 99.1% (97.4 to 99.7) and NPV of 99.0% 
(93.7 to 99.9) for index admission AMI. (Figure S5; Table S6).  
 
The pooled sensitivity for AMI for the index test among the cohorts(19,22-24) which used 
hs-cTnT for adjudication of AMI was marginally greater (99.0% (95.5% to 99.8%)) than 
that for other the cohorts which used other troponin assays (98.4% (94.7 to 99.5)).   
 
Discussion 
In this collaborative meta-analysis, a non-ischemic ECG plus hs-cTnT <5ng/L classified a 
substantial proportion of chest pain patients as being at low-risk of AMI in EDs in a 
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diverse sample of international locations. Integrating such an early screening approach 
into existing investigative strategies may enable patients to be safely discharged to 
outpatient follow-up earlier than in current practice.  
 
Nine included studies were classified as high risk of bias due to reported non-consecutive, 
non-random patient selection or exclusions due to missing data. Recruitment 24 hours a 
day, 7 days a week is extremely challenging in the ED setting and it is almost inevitable 
that some patients are excluded if only because of lack of available staff. In such 
situations, it would be of value if studies characterized excluded populations.  
 
The prevalence of AMI and the proportion of patients identified as low-risk varied 
between studies, allowing us to explore the clinical performance of this strategy in 
populations with different baseline risks. This is important because as this strategy does 
not include a formal assessment of risk factors or types of symptoms, decisions to 
override the strategy, or not, may vary considerably across sites and between attending 
physicians.  In this study the pooled sensitivity and NPV of this strategy was high, 
nevertheless two sites had much lower sensitivities (<90%)  than did the rest, the 
statistical heterogeneity was high, and the lower 95% confidence interval of the point 
estimate for sensitivity (96.6%) was less than the consensus goal of 99%(30), could mean 
the strategy is not universally safe.   Therefore, while the pooled estimates of sensitivity 
and NPV were good, it is not possible for us to make an unequivocal recommendation.  
 
The RATPAC cohort (sensitivity 89.6%) had a notably high proportion low-risk, was 
younger and with less co-morbidities than other cohorts and had low prevalence of AMI 
(8.0%). The Montpellier cohort was the smallest of the studies (n=194) and the low 
sensitivity (92.3%) was due to just 4 false negatives. While these two cohorts may be 
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considered statistical outliers and it may be possible to identify differences between these 
and other studies, we do not believe that it is justifiable to ignore them. It is likely that 
other settings will also have differences that result in low sensitivity. We recommend 
implementation be audited to ensure adequate safety.  
 
Since troponin may not be immediately detectable in the circulation following myocardial 
injury, some patients with AMI that present very early after onset of pain may not have 
detectable troponin. For this reason guidelines recommend a second sample 
approximately 3h after symptom onset in these patients.(6) As we observed 50% of false 
negatives had symptom onset within 3h of symptom onset, we recommend a cautious 
approach to implementation namely to exclude patients presenting soon after symptom 
onset. There is insufficient data to establish a minimum safe duration below 3h at this 
time.   
 
Using our search strategies we identified additional studies that have reported the use of 
ÔundetectableÕ hs-cTnT to rule out AMI in patients presenting with chest pain but were 
otherwise ineligible for inclusion in this meta-analysis. The largest was the registry study 
of Bandstein et al that reported of 8907 patients with initial hs-cTnT<5ng/L (61% of the 
cohort)  only 15 (0.17%) had an MI within 30 days where no ischemic changes had been 
noted on initial presentation(8) Other studies defined detectability thresholds using either 
the limit of blank (LoB; hs-cTnT <3 ng/l) or the limit of detection (LoD; hs-cTnT<5 ng/l). 
The studies by Aldous and colleagues report a sensitivity of hs-cTnT <LoB of 96%, 
inadequate for clinical use.(31,32) Other studies report sensitivities between 98.2% and 
100% for of hs-cTnT <LoD.		
(4,5,8,33-37).   
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Recent guidelines from the National Institute for Health Care and Excellence (NICE) and 
the European Society of Cardiology (ESC) have included diagnostic pathways where the  
first step is to rule out patients if the first measured hs-cTnT was less than the 
LoB(7)(NICE) or LoD(6).  A multi-centre analysis of the ESC pathway noted that hs-
cTnT<LoD was not responsible for any of the false negatives recorded.(38) In the 
systematic review that informed the NICE guidelines(7), five studies used LoB or LoD 
diagnostic thresholds. These studies were published near the time of the release of a 
technical bulletin (No: 12Ð023) by Roche Diagnostics which recommended recalibration 
of the hs-cTnT assay results from production batches 157120, 160197, and 163704 from 
2009 to 2012.(39) Consequently, some hs-cTnT results from the affected batches were 
incorrectly reported as lower than the true value (in the absence of recalibration). Wildi 
and colleagues compared results from the faulty assays to re-measured samples with an 
unaffected batch in 867 patients and demonstrated that the incorrect results negatively 
impacted on rule-out strategies using low concentrations of hs-cTnT.(40) Only one(41) of 
these studies addressed this issue directly and one other(4) reported to us that the batches 
were not affected.   
 
The absence of recalibration information in the cohort described by Bandstein et al.(8) 
may explain the large number of patients categorized as low-risk and why (with the 
exception of the low prevalence RATPAC cohort) the proportion of patients identified as 
low-risk of AMI in our analysis is much smaller. This is because samples with reported 
concentrations in the range of 3-8 ng/L, may be as much as 7 ng/L higher when correctly 
calibrated.(39,42) Importantly, the reported hs-cTnT result can easily change from below 
the LoD (pre-correction) to above the LoD after correction or re-measurement. Following 
correction the number of values that were below the LoD decreased from 71.0% to 
33.8%.(42) This present meta-analysis has carefully accounted for recalibration 
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requirements before performing any data analysis.  No data from mis-calibrated batches 
were included in our meta-analysis.  
 
The specificity of detectable hs-cTnT was, not surprisingly, poor, as to rule-in AMI is not 
the purpose of the proposed threshold, nor should it be used to identify patients at high-
risk of AMI.  Several hs-cTnT algorithms have been proposed and evaluated which 
include a separate rule-in hs-cTnT threshold.(38,43,44) 
 
The LoD or LoB are assay specific and future troponin T assays may have different 
values, therefore it is important to recognize that this analysis applies for a specific assay 
and not to the use of LoD or LoB of all assays.  Also, the analytical reliability of the LoD 
as a cut-off is vulnerable to manufacturer batch variation. Furthermore, variation in set-
up, calibration and operation of analyzers in laboratories at individual sites means that in 
practice it is optimistic to expect these assays to universally perform well and consistently 
at such low values. 
 
Limitations to this study included inter-cohorts variation in troponin assays used to 
adjudicate outcomes. There were also methodological differences for outcome 
adjudication between the studies including variation in the timing of late (second) 
reference troponin samples (Table S3). There was considerable heterogeneity which we 
were unable to assess by patient level meta-regression because patient specific data could 
not be shared.  Seven studies identified as possibly meeting inclusion criteria declined to 
participate or did not respond to the invitation. Based on the apparent timing of hs-cTnT 
measurement, four of those studies may have used assay batches affected by the 
calibration error.    
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Future research should include an assessment of the current strategy in combination with 
a validated diagnostic strategy which accounts for risk factors and symptoms on 
presentation such as found in the History ECG Age Risk Troponin (HEART)(45), 
ADAPT(46) or Emergency Department Assessment of Chest pain Score (EDACS) 
pathways(47).  NICE have recently recommended this approach in conjunction with an 
LoD strategy.(48) The incorporation of risk and symptoms may reassure physicians of the 
safety of the early rule-out strategy, although possibly at the risk of lower efficacy.  
Second, further research on hs-cTnT kinetics is needed to establish the minimum safe 
duration post symptom onset for the first blood sample. Third, a pragmatic 
implementation trial to assess the strategy performance in a Òreal-lifeÓ emergency 
department setting is required.  This may include assessments of the cost-efficacy and 
cost-benefit of the strategy. 
 
Conclusion 
This meta-analysis of eleven clinically and geographically diverse cohorts using hs-cTnT 
results assessed the safety of an early rule-out strategy for AMI. In most, but not all 
settings, patients investigated for Acute Coronary Syndrome with hs-cTnT<LoD and a 
non-ischemic ECG had very low risk of AMI or 30-day MACE. The point estimate for 
sensitivity was 98.7% (96.6% to 99.5%). AMI may be ruled out in a substantial 
proportion of patients after only one blood draw.  We do not recommend at this time a 
single blood draw strategy be used in those presenting within 3 hours of symptom onset. 
Moreover, because the strategy had considerable heterogeneity in sensitivity between sites 
this strategy should not be used without careful additional clinical assessment to identify 
those patients at high likelihood of underlying critical coronary stenosis. Local audits of 
implementation should take place to ensure safety and efficacy. 
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Figures legends 
 
 
Figure 1: CONSORT diagram. Flow diagram describing the process to identify cohorts. 
ECG: Electrocardiogram. Hs-cTnT: High sensitivity cardiac troponin T 
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Figure 2: Forest plots for AMI or the summary estimates for Sensitivity. APACE: Advantageous Predictors of Acute Coronary Syndromes 
Evaluation. ADAPT: 2h Accelerated Diagnostic protocol to Assess Patients with chest pain symptoms using contemporary Troponins as the only 
biomarker study. RATPAC: Randomised Assessment of Treatment using Panel Assay of Cardiac Markers 
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Figure 3: Forest plots for AMI or the summary estimates for Negative Predictive Value. APACE: Advantageous Predictors of Acute Coronary 
Syndromes Evaluation. ADAPT: 2h Accelerated Diagnostic protocol to Assess Patients with chest pain symptoms using contemporary Troponins as 
the only biomarker study. RATPAC: Randomised Assessment of Treatment using Panel Assay of Cardiac Markers 
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Table 1: Cohort Characteristics 
 Lund      
(28) 
RATPAC 
(21)  
ADAPT-
Brisbane 
(20) 
 
Nelson    
(22) 
 
Paris      
(25) 
Manchester
(4) 
Leeuwarden 
(27) 
APACE 
(19) 
Heidelberg 
(24) 
ADAPT-
Christchurch
(20) 
Montpellier
(23) 
Country Sweden United 
Kingdom 
Australia New 
Zealand 
France United 
Kingdom 
Netherlands Switerzland; 
Spain; Italy 
Germany New Zealand France 
n 1138 833 832 452 304 653 261 2831 658 1113 194 
Age (years) 60.6 ± 17.5 54.8 ± 13.8 54.5 (45-65) 63 ± 14.5 ? 57 ± 17 58.6 ± 14.3 62 62 (49-74) 70.6 ± 12.7 65.3 ± 13 60.5 ± 17.5 
Male (%) 54.6 59.8 61.2 60 64.1 61.2 61 70.6 64 65.2 63.4 
eGFR 
(ml/min/1.73
m
2
) 
84 ± 26  NA 85 (70-90)  NA 80 ± 29 80.8 ±  21.5  NA 85 (69-101) 66.6 ± 29.1 71 (57-84) 91 ± 32.5 
Creatinine 
(umol/l) 
85 ± 48 82.4 ± 24 84.0 ± 44.1  NA 89 ± 44 84.5  ± 28.4  NA 82 ± 35  NA 96 ± 41 86 ± 80 
Diabetes 13.9 8.2 13  NA 13.5 17.8  NA 18 33.6 17.8 14.4 
Hypertension 43.5 35.2 43.5  NA 36.8 48.8  NA 63.9 83.2 67.8 34.0 
Dyslipidemia 22.6 23.6 42.7  NA 36.5 48.2  NA 51.9 59.5 63.5 34.0 
Family 
history of 
IHD 
22.6 31.8 46.2  NA 31.9 48.1  NA 33.4 21.4 67.2 NA 
Smoker 13.0 28.6 27.8  NA 40.1 30.7  NA 64.1 12.0 42.8 34.0 
Prior MI 19.9 5.8 17.1  NA 26.0 23.8  NA 24.4 NA 33.3 4.1 
Prior Stroke 9.0  NA  9.3  NA NA  10.1  NA 5.6 7.4  NA  NA 
Prior 
hospitalisatio
n for CHF 
NA  NA  4.8  NA NA   NA   NA  NA  20.5  NA  NA 
Aspirin use 28.6 18.7 26.1  NA NA  42.7  NA 37.7 NA 62 NA 
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Data presented as percentage, mean ± standard deviation or median (lower quartile-upper quartile range) 
eGF: estimated Glomerular Filtration Rate, MI = Myocardial Infarction; COPD: Chronic Obstructive Pulmonary Disease; ACE/ARB: Angiotensin Converting Enzyme 
inhibitors/Angiotensin II Receptor Blockers; CHF: Chronic Heart Failure; IHD: Ischemic Heart Disease 
APACE: Advantageous Predictors of Acute Coronary Syndromes Evaluation. ADAPT: 2h Accelerated Diagnostic protocol to Assess Patients with chest pain symptoms using 
contemporary Troponins as the only biomarker study. RATPAC: Randomised Assessment of Treatment using Panel Assay of Cardiac Marker 
 
 
COPD 7.4  NA   NA   NA NA   NA   NA 10.9 15.7  NA  NA 
Beta-blocker 30.4  NA  19.6  NA NA  24.2  NA 35.6 NA 47.2 23.2 
ACE/ARB 30.8  NA  18.3  NA NA  23.5  NA 40.4 NA 35 23.2 
Statins 29.8  NA  27.3  NA NA  44.2  NA 36.8 NA 50.2 NA 
Length of 
stay (days) 
NA  NA 1.1 (0.4-3.0)  NA NA  2 (2 - 6)  NA 1 (0-5) NA 2 (1-5) NA 
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